Recomendações na Abordagem da Esclerose Lateral Amiotrófica

Mariana Saavedra, Filipa Pereira, Bernardo Moreno, Maria João Vidal Azevedo

Resumo


A esclerose lateral amiotrófica (ELA) é a doença do neurónio motor mais comum com início na idade adulta. Envolve os neurónios motores superiores e inferiores com degeneração progressiva dos motoneurónios. Não existe cura, sendo inexoravelmente fatal, pelo que o tratamento sintomático e de reabilitação assumem uma importância vital. Esta revisão pretende agrupar o conhecimento corrente acerca do diagnóstico e tratamento da ELA de uma forma sistematizada, abrangente e prática de consultar, adaptada à realidade portuguesa. Foi efetuada uma revisão da literatura focada no tratamento e reabilitação da esclerose lateral amiotrófica de publicações com ênfase nos últimos 10 anos.


Palavras-chave


Esclerose Lateral Amiotrófica, Reabilitação, Equipas de Saúde, Planeamento em Saúde

Texto Completo:

PDF

Referências


Andersen P, Abrahams S, Borasio G, Carvalho M, Chioe A, Van Dammef P, et al. EFNS guidelines on the Clinical Management of Amyotrophic Lateral Sclerosis (MALS) – revised report of an EFNS task force. Eur J Neurol. 2012; 19: 350–75.

Forsgren L, Almay BG, Holmgren G, Wall S. Epidemiology of motor neuron disease in northern Sweden. Acta Neurol Scand. 1983; 68: 20–9.

Alonso A, Logroscino G, Jick SS, Hernan MA. Incidence and lifetime risk of motor neuron disease in the United Kingdom: a population-based study. Eur J Neurol. 2009;16: 745–51. doi: 10.1111/j.1468-1331.2009.02586.x.

Chio,A, Mora, G, Calvo, A, Mazzini, L, Bottacchi E, Mutani R. Epidemiology of ALS in Italy: A 10-year prospective population-based study. Neurology. 2009; 72: 725-31.

Miller RG, Mitchell JD, Moore DH. Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND) 2012. Cochrane Database Syst Rev. 2012;2012:CD001447. doi: 10.1002/14651858.CD001447

Andersen P, Abrahams S, Borasio G, Carvalho M, Chioe A, Van Dammef P, et al. Management of amyotrophic lateral sclerosis. In: Gilhus NE, Barnes MP, Brainin M eds. European Handbook of Neurological Management, 2nd ed.. Chichester: Wiley-Blackwell; 2010. p. 283–310.

Hardiman O, van den Berg LH, Kiernan MC. Clinical diagnosis and management of amyotrophic lateral sclerosis. Nat Rev Neurol. 2011;7:639-49.

Wijesekera LC, Leigh PN. Amyotrophic lateral sclerosis. Orphanet J Rare Dis. 2009; 4:3.

Xerez DR. Reabilitação na Esclerose Lateral Amiotrófica: revisão da literatura. Acta Fisiátrica São Paulo. 2008;15:182-8.

Kimura F, Fujimura C, Ishida S, Nakajima H, Furutama D, Uehara H, et al. Progression rate of ALSFRS-R at time of diagnosis predicts survival time in ALS. Neurology. 2006;66:265-7.

Kaufmann P, Levy G, Thompson JL, Delbene ML, Battista V, Gordon PH, et al. The ALSFRSr predicts survival time in an ALS clinic population. Neurology. 2005;64:38-43.

Turner MR, Talbot K. Mimics and chameleons in motor neurone disease. Pract Neurol. 2013;13:153-64. doi: 10.1136/practneurol-2013-000557.

Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2001; 1:293-9.

Carvalho M, Swash M. Awaji diagnostic algorithm increases sensitivity of El Escorial criteria for ALS diagnosis. Amyotroph Lateral Scler. 2009; 10: 53–7.

Douglass CP, Kandler RH, Shaw PJ, McDermott CJ. An evaluation of neurophysiological criteria used in the diagnosis of motor neurone disease. J Neurol Neurosurg Psychiatry. 2010; 81: 646–9.

Schrooten M, Smetcoren C, Robberecht W, Van Damme P. Benefit of the Awaji diagnostic algorithm for amyotrophic lateral sclerosis: a prospective study. Ann Neurol. 2011; 70: 79–83.

Okita T, Nodera H, Shibuta Y, Nodera A, Asanuma K, Shimatani Y, et al. Can Awaji ALS criteria provide earlier diagnosis than the revised El Escorial criteria? J Neurol Sci. 2011; 302: 29–32.

Miller RG, Jackson CE, Kasarskis EJ. Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology. 2009;73:1218-26. doi: 10.1212/WNL.0b013e3181bc0141.

Bensimon G, Lacomblez L, Delumeau JC, Bejuit R, Truffinet P, Meininger V. A study of riluzole in the treatment of advanced stage or elderly patients with amyotrophic lateral sclerosis. J Neurol. 2002; 249: 609–15.

Cruz MP. Edaravone (radicava). A novel neuroprotective agent for the treatment of amyotrophic lateral sclerosis. P T . 2018;43:25-8.

Majmudar S, Wu J, Paganoni S. Rehabilitation in amyotrophic lateral sclerosis: why it matters. Muscle Nerve. 2014; 50: 4–13. doi:10.1002/mus.24202.

Paganoni S, Karam C, Joyce N, Bedlack R, Carter GT. Comprehensive rehabilitative care across the spectrum of Amyotrophic Lateral Sclerosis. NeuroRehabilitation.2015;37: 53–68.

Dal Bello-Haas V, Florence JM. Therapeutic exercise for people with amyotrophic lateral sclerosis or motor neuron disease. Cochrane Database Syst Rev. 2013;31:5:CD005229.

Chen A, Montes J, Mitsumoto H. The Role of Exercise in Amyotrophic Lateral Sclerosis. Phys Med Rehabil Clin N Am. 2008; 19: 545–57.

Almeida JP, Silvestre R, Pinto AC, Carvalho M. Exercise and amyotrophic lateral sclerosis. Neurol Sci. 2012;33:9-15.

Drory VE, Goltsman E, Reznik JG Mosek A, Korczyn AD. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J Neurol Sci. 2001; 91: 133-7.

Bello-Haas VD, Florenc, JM, Kloos AD, Scheirbecker LG, Hayes SM, Pioro EP, et al. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology. 2007; 68: 2003-7. doi:

1212/01.wnl.0000264418.92308.a4.

Majmudar S, Wu J, Paganoni S. Rehabilitation In Amyotrophic Lateral Sclerosis: Why It Matters. Muscle Nerve. 2014; 50: 4–13. doi:10.1002/mus.24202.

Macpherson CE, Clare C. Pulmonary physical therapy techniques to enhance survival in amyotrophic lateral sclerosis: a systematic review. J Neurol Phys Ther. 2016;40:165-75. doi: 10.1097/NPT.0000000000000136.

Pinto S, Carvalho M. Can inspiratory muscle training increase survival in early-affected amyotrophic lateral sclerosis patients? Amyotroph Lateral Scler Frontotemporal Degener. 2013;14:124-6. doi:

3109/17482968.2012.726227.

Pinto S, Pinto A, de Carvalho M. Phrenic nerve studies predict survival in amyotrophic lateral sclerosis. Clin Neurophysiol. 2012;123:2454-9. doi: 10.1016/j.clinph.2012.05.012.

Vignola A, Guzzo A, Calvo A, Moglia C, Pessia A, Cavallo E, et al. Anxiety undermines quality of life in ALS patients and caregivers. Eur J Neurol. 2008; 15: 1231–6.

Wicks P, Abrahams S, Masi D, Hejda-Forde S, Leigh PN, Goldstein LH. Prevalence of depression in a 12-month consecutive sample of patients with ALS. Eur J Neurol. 2007; 14: 993–1001.

Elman LB, Siderowf A, Houseman G, Kelley M, McCluskey LF. Venous thrombosis in an ALS population over four years. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6: 246–9.

Qureshi MM, Cudkowicz ME, Zhang H, Raynor E. Increased incidence of deep venous thrombosis in ALS. Neurology. 2007; 68: 76–7.

Gil J, Funalot B, Verschueren A. Causes of death amongst French patients with amyotrophic lateral sclerosis: a prospective study. Eur J Neurol. 2008; 15: 1245– 51.

Ng L, Khan F, Young CA, Galea M. Symptomatic treatments for amyotrophic lateral sclerosis/motor neuron disease. Cochrane Database Syst Rev. 2017. 1:CD011776. doi: 10.1002/14651858.CD011776.pub2.

Marin B, Desport JC, Kajeu P, Jesus P, Nicolaud B, Nicol M, et al. Alteration of nutritional status at diagnosis is a prognostic factor for survival of amyotrophic lateral sclerosis patients. J Neurol Neurosurg Psychiatry. 2011; 82: 628–34.

Abrahams S, Leigh PN, Goldstein LH. Cognitive change in ALS: a prospective study. Neurology. 2005; 64: 1222–6.

Flaubert JL, Spicer CM, Jette AM, editors. The Promise of Assistive Technology to Enhance Activity and Work Participation. Washington: National Academies Press; 2017.

Fundação PT Soluções Especiais PT [consultado 2018 Junho] Disponível em: http://www.fundacao.telecom.pt [homepage na Internet].

Ringholz GM, Appel SH, Bradshaw M, Cooke NA, Mosnik DM, Schulz PE. Prevalence and patterns of cognitive impairment in sporadic ALS. Neurology. 2005; 65: 586–90.

Panigni F. Psychological wellbeing and quality of life in amyotrophic lateral sclerosis: A review. Int J Psychol. 2013;48:194-205. doi: 10.1080/00207594.2012.691977.

Harris M, Thomas G, Thomas M, Cafarella P, Stocks A, Greig J, McEvoy RD. Supporting wellbeing in motor neurone disease for patients, carers, social networks, and health professionals: A scoping review and synthesis. Palliat Support Care. 2018;16:228-37. doi: 10.1017/S1478951517000700.

Mitsumoto H, Bromberg M, Johnston W, Tandan R, Byock I, Lyon M et al. Promoting excellence in end-of-life care in ALS. Amyotroph Lateral Scler Other Motor Neuron Disord. 2005; 6: 145–54.




DOI: http://dx.doi.org/10.25759/spmfr.285

Apontamentos

  • Não há apontamentos.


Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Revista da Sociedade Portuguesa de Medicina Física e de Reabilitação